DOCSLIB.ORG

(12) Patent Application Publication (10) Pub. No.: US 2017/0042791 A1 Ghalili Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) Patent Application Publication (10) Pub. No.: US 2017/0042791 A1 Ghalili Et Al US 20170042791A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2017/0042791 A1 Ghalili et al. (43) Pub. Date: Feb. 16, 2017 (54) TOPICAL COMPOSITIONS COMPRISING A6IR 8/73 (2006.01) HYDROXY ACIDS AND CANNABINOIDS A6IR 8/92 (2006.01) FOR SKIN CARE A6IR 9/00 (2006.01) A6II 45/06 (2006.01) (71) Applicant: Kannannovations LLC, New York, A636/85 (2006.01) NY (US) A6II 3/19 (2006.01) A6II 3/94 (2006.01) (72) Inventors: Babek Ghalili, New York, NY (US); A63L/92 (2006.01) Kevin McGovern, Palm Beach, FL A63L/366 (2006.01) (US) A61O 19/00 (2006.01) (52) U.S. Cl. (73) Assignee: Kannannovations LLC, New York, CPC ................. A61K 8/97 (2013.01); A61O 19/00 NY (US) (2013.01); A61O 19/08 (2013.01); A61K 8/365 (2013.01); A61K 8/498 (2013.01); A61K 8/345 (21) Appl. No.: 15/233,251 (2013.01); A61K 8/731 (2013.01); A61K 8/922 (22) Filed: Aug. 10, 2016 (2013.01); A61K 9/0014 (2013.01); A61 K 45/06 (2013.01); A61K 36/185 (2013.01); Related U.S. Application Data A61K 31/19 (2013.01); A61K 31/194 (2013.01); A61K 31/192 (2013.01); A61 K (60) Provisional application No. 62/203,698, filed on Aug. 3 1/366 (2013.01) 11, 2015. Publication Classification (57) ABSTRACT (51) Int. Cl. The present invention relates to compositions and methods A 6LX 8/97 (2006.01) for the prevention and treatment of skin disorders and for the A61O 19/08 (2006.01) rejuvenation of the skin. In particular, the application A6 IK 8/365 (2006.01) describes topical compositions and methods of treatments A6I SA9 (2006.01) comprising the combined use of one or more cannabinoids A6 IK 8/34 (2006.01) and one or more hydroxy acids in a suitable carrier. Patent Application Publication Feb. 16, 2017. Sheet 1 of 5 US 2017/0042791 A1 FIGURE 1 Tetrahydrocannabinol (THC) Tetrahydrocannabinol Carboxylic Acid (THCA) Cannabidiol (CBD) Cannabidiol Carboxylic Acid (CBDA) Patent Application Publication Feb. 16, 2017. Sheet 2 of 5 US 2017/0042791 A1 FIGURE 1 (continued) Cannabigerol (CBG) HO Cannabichromene (CBC) Cannabinol (CBN) Tetrahydrocannabivarin (THCV) Patent Application Publication Feb. 16, 2017 Sheet 3 of 5 US 2017/0042791 A1 FIGURE 2 Baseline Day 28 Patent Application Publication Feb. 16, 2017. Sheet 4 of 5 US 2017/0042791 A1 FIGURE 3 Patent Application Publication Feb. 16, 2017 Sheet 5 of 5 US 2017/0042791 A1 FIGURE 4 Baseline Day 28 US 2017/0042791 A1 Feb. 16, 2017 TOPCAL COMPOSITIONS COMPRISING 0006. Accordingly, there is a need in the art for improved HYDROXY ACDS AND CANNABINOIDS treatment options for improving skin condition, delaying FOR SKN CARE and reducing the effects of skin aging and treating or preventing skin disorders. CROSS-REFERENCE TO RELATED APPLICATIONS SUMMARY OF THE INVENTION 0007. It is, therefore, an object of the invention to provide 0001. This application claims the benefit of priority from Solutions to the aforementioned problems, among other U.S. Provisional Application No. 62/203,698, filed Aug. 11, objects. 2015, the content of which is incorporated by reference in its 0008. One embodiment of the invention is a topical entirety. composition for treating skin that comprises a therapeuti cally effective amount of at least one cannabinoid and a FIELD OF THE INVENTION therapeutically effective amount of a hydroxy acid in a topically acceptable carrier. The at least one cannabinoid and 0002 The present invention relates to the use of hydroxy at least one hydroxy acid may optionally be the only active acids and cannabinoids for skin care. ingredients of the composition. In one aspect of the inven tion, the cannabinoids are present in the topical composition BACKGROUND OF THE INVENTION in a concentration between 0.1 and 30% by weight of the composition. Preferably, the cannabinoids are one or more 0003. The skin is the largest organ of the body, with a of a natural phytocannabinoid, an organic cannabinoid, an Surface area of 18 Square feet. In the epidermis, the kera endocannabinoid, a cannabinoid analog, a cannabinoid tinocytes produce keratin, a protein that gives skin its derivative, a synthetic cannabinoid and a cannabinoid recep strength and flexibility and waterproofs the skin surface. tor agonist. The hydroxy acid is an alpha hydroxy acid, a Collagen and elastic fibers in the dermis give strength to the beta hydroxy acid or a combination thereof. In one aspect of skin. The skin is continuously exposed to changes in the the invention, the hydroxy acid is an alpha hydroxy acid, and external environment, including oxidative insults, heat, cold, the alpha hydroxy acid is lactic acid, citric acid, glycolic UV radiation, injury, and mechanical stresses. The stratum acid, mandelic acid, benzylic acid, malic acid, tartaric acid, corneum, composed of terminally differentiated keratino gluconolactone, galactonolactone, glucuronolactone, galac cytes, constitutes the natural barrier that prevents loss of turonolactone, gulonolactone, ribonolactone, Saccharic acid water and penetration of infectious agents, such as bacteria lactone, pantoylactone, glucoheptonolactone, mannonolac and viruses, and foreign particles. Keratin intermediate tone, or galactoheptonolactone. In a different aspect of the filaments provide the cells with mechanical resilience and invention, the hydroxy acid is a beta hydroxy acid, and the protects them against physical stress. Disruption of the beta hydroxy acid is salicylic acid or lipohydroxy acid. keratin scaffold leads to tissue and cell fragility in the skin 0009. In one aspect of the invention, the cannabinoid is and its appendages (hair, nail, glands), oral mucosa, and hemp oil or human breast milk. cornea, and exposes the skin to pathological conditions and 0010. In a different aspect of the invention, the cannabi diseases. noid is one or more of cannabigerolic acid (CBGA), can nabigerolic acid monomethylether (CBGAM), cannabigerol 0004 Dermatitis, also known as eczema, is an inflam (CBG), cannabigerol monomethylether (CBGM), cannab mation of the skin that is characterized by the presence of igerovarinic acid (CBGVA), cannabigerovarin (CBGV), itchy, erythematous, Vesicular, weeping, and crusting cannabichromenic acid (CBCA), cannabichromene (CBC), patches. Inflammatory agents include bacteria, fungi, cannabichromevarinic acid (CBCVA), cannabichromevarin viruses, and autoimmune, allergic, hormonal and malignant (CBCV), cannabidiolic acid (CBDA), cannabidiol (CBD), inflammatory agents. The most common skin diseases or cannabidiol monomethylether (CBDM), cannabidiol-C disorders include eczema, psoriasis, dermatitis, itching der (CBD-C), cannabidivarinic acid (CBDVA), cannabidivarin matosis, rosacea, perioral dermatitis, acne, non-melanoma (CBDV), cannabidiorcol (CBD-C), delta-9-tetrahydrocan skin cancer and melanoma. Although symptoms vary, recur nabinolic acid A (THCA-A), delta-9-tetrahydrocannabinolic rent dermatitis conditions include pruritus, dryness and skin acid B (THCA-B), delta-9-tetrahydrocannabinol (THC), rashes, which may be accompanied by redness, skin Swell delta-9-tetrahydrocannabinolic acid-C (THCA-C), delta ing, itching and dryness, crusting, flaking, blistering, crack 9-tetrahydrocannabinol-C (THC-C), delta-9-tetrahydro ing, oozing, or bleeding. Common forms of dermatitis cannabivarinic acid (THCVA), delta-9-tetrahydrocannabi include atopic dermatitis, an allergic disease characterized varin (THCV), delta-9-tetrahydrocannabiorcolic acid by the presence of itchy rashes, contact dermatitis, which (THCA-C), delta-9-tetrahydrocannabiorcol (THC-C), may be caused by an allergen or an irritant, Xerotic eczema, delta-7-cis-iso-tetrahydrocannabivarin, delta-8-tetrahydro which is caused by dry skin, and seborrheic dermatitis, cannabinolic acid (A-THCA), delta-8-tetrahydrocannabinol which is more common in infants. (A-THC), cannabicyclolic acid (CBLA), cannabicyclol 0005 Sunlight is a major cause of skin aging. Symptoms (CBL), cannabicyclovarin (CBLV), cannnabielsoic acid A of skin aging are wrinkles, age spots and dryness. While (CBEA-A), cannabielsoic acid B (CBEA-B), cannabielsoin treatment with moisturizers and steroid creams may tempo (CBE), cannabinolic acid (CBNA), cannabinol (CBN), can rarily control skin disorder and aging symptoms by reducing nabinol methylether (CBNM), cannabinol-C (CBN C), inflammation and Smoothing wrinkles, the relief is only cannabivarin (CBV), cannabinol-C (CBN C), cannabior temporary. There is no known cure for dermatitis, and col (CBN C), cannabinodiol (CBND), cannabinodivarin systemic side effects prevent long term treatment of chronic (CBVD), cannabitriol (CBT), 10-ethoxy-9-hydroxy-delta dermatological conditions with steroids. 6a-tetrahydrocannabinol, 8,9-dihydroxy-delta-6a-tetrahy US 2017/0042791 A1 Feb. 16, 2017 drocannabinol, cannabitriolvarin (CBTV), ethoxy-cannabit about 1 umol/cm. In one aspect of the invention, the subject riolvarin (CBTVE), dehydrocannabifuran (DCBF), is a mammal. In a preferred aspect of the invention, the cannabifuran (CBF), cannabichromanon (CBCN), can mammal is a human. nabicitran (CBT), 10-oxo-delta-6a-tetrahydrocannabinol 0017. In yet another embodiment, the invention provides (OTHC), delta-9-cis-tetrahydrocannabinol (cis-THC), 3,4,5, a method for treating or preventing pruritus, dryness of the 6-tetrahydro-7-hydroxy-alpha-alpha-2-trimethyl-9-n-pro skin, skin rash, redness, Swelling of the skin, itching, crust pyl-2,6-methano-2H-1-benzoxocin-5-methanol (OH-iso ing, flaking, blistering, cracking, oozing, bleeding or blis HHCV), cannabiripsol (CBR) and trihydroxy-delta-9- tering of the skin in a Subject in need thereof, that comprises
Load more

Recommended publications
  • List of Union Reference Dates A
    Active substance name (INN) EU DLP BfArM / BAH DLP yearly PSUR 6-month-PSUR yearly PSUR bis DLP (List of Union PSUR Submission Reference Dates and Frequency (List of Union Frequency of Reference Dates and submission of Periodic Frequency of submission of Safety Update Reports, Periodic Safety Update 30 Nov. 2012) Reports, 30 Nov.
    [Show full text]
  • Lamisil Versus Clotrimazole in the Treatment of Vulvovaginal Candidiasis
    Volume 5 Number 1 (March 2013) 86-90 Lamisil versus clotrimazole in the treatment of vulvovaginal candidiasis Ali Zarei Mahmoudabadi1,2, Mahin Najafyan3, Eskandar Moghimipour4, Maryam Alwanian1, Zahra Seifi1 1Department of Medical Mycology, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran. 2Infectious Diseases and Tropical Medicine Centre, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran. 3Department of Obstetric and Genecology, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran. 4Department of Pharmaceutics, School of Pharmacy, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran. Received: March 2012, Accepted: October 2012. ABSTRACT Background and Objectives: Vaginal candidiasis is a common disease in women during their lifetime and occurs in diabetes patients, during pregnancy and oral contraceptives users. Although several antifungals are routinely used for treatment; however, vaginal candidiasis is a challenge for patients and gynecologists. The aim of the present study was to evaluate terbinafine (Lamisil) on Candida vaginitis versus clotrimazole. Materials and Methods: In the present study women suspected to have vulvovaginal candidiasis were sampled and disease confirmed using direct smear and culture examination from vaginal discharge. Then, patients were randomly divided into two groups, the first group (32 cases) was treated with clotrimazole and the next (25 cases) with Lamisil. All patients were followed-up to three weeks of treatment and therapeutic effects of both antifungal were compared. Results: Our results shows that 12 (37.5%) patients were completely treated with clotrimazole during two weeks and, 6(18.8%) patients did not respond to drugs and were refereed for fluconazole therapy. Fourteen (43.8%) patients showed moderate response and clotrimazole therapy was extended for one more week.
    [Show full text]
  • PDF of the Full Text
    Clinical Pharmacokinetics of Cannabinoids Franjo Grotenhermen ABSTRACT. Absorption and metabolism of tetrahydrocannabinol (THC) vary as a function of route of administration. Pulmonary assimilation of in- haled THC causes a maximum plasma concentration within minutes, while psychotropic effects start within seconds to a few minutes, reach a maxi- mum after 15 to 30 minutes, and taper off within 2 to 3 hours. Following oral ingestion, psychotropic effects set in with a delay of 30 to 90 minutes, reach their maximum after 2 to 3 hours, and last for about 4 to 12 hours, de- pending on dose and specific effect. The initial volume of distribution of THC is small for a lipophilic drug, equivalent to the plasma volume of about 2.5-3 L, reflecting high protein binding of 95-99%. The steady state volume of distribution has been esti- mated to be about 100 times larger, in the range of about 3.5 L per kg of body weight. The lipophility of THC with high binding to tissue and in par- ticular to fat, the major long-term storage site, causes a change of distribu- tion pattern over time. Only about 1% of THC administered IV is found in the brain at the time of peak psychoactivity. THC crosses the placenta and small amounts penetrate into the breast milk. Metabolism of THC occurs mainly in the liver by microsomal hydroxylation and oxidation catalyzed by enzymes of the cytochrome P-450 complex. In man, the C-11 carbon is the major site attacked. Hydroxylation results in 11-hydroxy-THC (11-OH-THC) and further oxi- dation to 11-nor-9-carboxy-THC (THC-COOH), which may be glucuronated to THC-COOH beta-glucuronide.
    [Show full text]
  • What Is Delta-8 THC?? Cannabinoid Chemistry 101
    What is Delta-8 THC?? Cannabinoid Chemistry 101 National Conference on Weights and Measures Annual Meeting - Rochester, NY Matthew D. Curran, Ph.D. July 21, 2021 Disclaimer Just to be clear… • I am a chemist and not a lawyer so: • This presentation will not discuss the legal aspects of Δ8-THC or DEA’s current position. • This presentation will not discuss whether Δ8-THC is considered “synthetic” or “naturally occurring.” • This is not a position statement on any issues before the NCWM. • Lastly, this should only be considered a scientific sharing exercise. Florida Department of Agriculture and Consumer Services 2 Cannabis in Florida Cannabis Syllabus • What is Cannabis? • “Mother” Cannabinoid • Decarboxylation • Relationship between CBD and THC • What does “Total” mean? • Dry Weight vs. Wet Weight • What does “Delta-9” mean? • Relationship between “Delta-8” and “Delta-9” • CBD to Delta-8 THC • Cannabinoid Chemistry 202… Florida Department of Agriculture and Consumer Services 3 Cannabis Cannabis • Cannabis sativa is the taxonomic name for the plant. • The concentration of Total Δ9-Tetrahydrocannabinol (Total Δ9-THC) is critical when considering the varieties of Cannabis sativa. • Hemp – (Total Δ9-THC) 0.3% or less • Not really a controversial term, “hemp” • Marijuana/cannabis – (Total Δ9-THC) Greater than 0.3% • Controversial term, “marijuana” • Some states prohibit the use of this term whereas some states have it in their laws. • Some states use the term “cannabis.” • Not italicized • Lower case “c” Florida Department of Agriculture and
    [Show full text]
  • Dermatologic Medication in Pregnancy
    Marušić et al. Acta Dermatovenerol Croat Subcutaneous dirofilariasis Acta Dermatovenerol Croat 2009;17(1):40-47 REVIEW Dermatologic Medication in Pregnancy Petra Turčić1, Zrinka Bukvić Mokos2, Ružica Jurakić Tončić2, Vladimir Blagaić3, Jasna Lipozenčić2 1School of Pharmacy and Biochemistry, University of Zagreb; 2University Department of Dermatology and Venereology, Zagreb University Hospital Center and School of Medicine; 3University Department of Obstetrics and Gynecology, Sveti Duh General Hospital, Zagreb, Croatia Corresponding author: SUMMARY In female body, a vast number of skin changes occur Petra Turčić, Phar. M. during pregnancy. Some of them are quite distressing to many women. Department of Pharmacology Therefore, performing treatment for physiologic skin changes during pregnancy with antiinfective agents, glucocorticosteroids, topical School of Pharmacy and Biochemistry immunomodulators, retinoids, minoxidil, etc., is discussed. Drug University of Zagreb administration during pregnancy must be reasonable. Domagojeva 2 KEY WORDS: dermatologic medication, pregnancy, physiologic skin HR-10000 Zagreb changes, treatment Croatia [email protected] Received: September 1, 2008 Accepted: January 9, 2009 INTRODUCTION In female body, a vast number of changes oc- bolic imbalances (3), diabetes and cardiovascular cur during pregnancy. Some of them are quite diseases (4). Pregnancy extends and alters the distressing to many women. Therefore, perform- impact of sex differences on absorption, distribu- ing treatment for these changes during pregnancy tion, metabolism and elimination (5). Cardiac out- is discussed. Normal pregnancy needs to avoid put is elevated early and remains elevated for the harmful drugs, both prescribed and over-the coun- remainder of pregnancy. Regional blood flow can ter, and drugs of abuse, including cigarettes, alco- change, with some areas of the skin having sub- hol as well as occupational and environmental ex- stantial increases in blood flow during the course posure to potentially harmful chemicals.
    [Show full text]
  • The Use of Cannabinoids in Animals and Therapeutic Implications for Veterinary Medicine: a Review
    Veterinarni Medicina, 61, 2016 (3): 111–122 Review Article doi: 10.17221/8762-VETMED The use of cannabinoids in animals and therapeutic implications for veterinary medicine: a review L. Landa1, A. Sulcova2, P. Gbelec3 1Faculty of Medicine, Masaryk University, Brno, Czech Republic 2Central European Institute of Technology, Masaryk University, Brno, Czech Republic 3Veterinary Hospital and Ambulance AA Vet, Prague, Czech Republic ABSTRACT: Cannabinoids/medical marijuana and their possible therapeutic use have received increased atten- tion in human medicine during the last years. This increased attention is also an issue for veterinarians because particularly companion animal owners now show an increased interest in the use of these compounds in veteri- nary medicine. This review sets out to comprehensively summarise well known facts concerning properties of cannabinoids, their mechanisms of action, role of cannabinoid receptors and their classification. It outlines the main pharmacological effects of cannabinoids in laboratory rodents and it also discusses examples of possible beneficial use in other animal species (ferrets, cats, dogs, monkeys) that have been reported in the scientific lit- erature. Finally, the article deals with the prospective use of cannabinoids in veterinary medicine. We have not intended to review the topic of cannabinoids in an exhaustive manner; rather, our aim was to provide both the scientific community and clinical veterinarians with a brief, concise and understandable overview of the use of cannabinoids in veterinary
    [Show full text]
  • Storozhuk and Zholos-MS CN
    Send Orders for Reprints to [email protected] Current Neuropharmacology, 2018, 16, 137-150 137 REVIEW ARTICLE TRP Channels as Novel Targets for Endogenous Ligands: Focus on Endo- cannabinoids and Nociceptive Signalling Maksim V. Storozhuk1,* and Alexander V. Zholos1,2,* 1A.A. Bogomoletz Institute of Physiology, National Academy of Science of Ukraine, 4 Bogomoletz Street, Kiev 01024, Ukraine; 2Educational and Scientific Centre “Institute of Biology and Medicine”, Taras Shevchenko Kiev National University, 2 Academician Glushkov Avenue, Kiev 03022, Ukraine Abstract: Background: Chronic pain is a significant clinical problem and a very complex patho- physiological phenomenon. There is growing evidence that targeting the endocannabinoid system may be a useful approach to pain alleviation. Classically, the system includes G protein-coupled receptors of the CB1 and CB2 subtypes and their endogenous ligands. More recently, several sub- types of the large superfamily of cation TRP channels have been coined as "ionotropic cannabinoid receptors", thus highlighting their role in cannabinoid signalling. Thus, the aim of this review was to explore the intimate connection between several “painful” TRP channels, endocannabinoids and nociceptive signalling. Methods: Research literature on this topic was critically reviewed allowing us not only summarize A R T I C L E H I S T O R Y the existing evidence in this area of research, but also propose several possible cellular mechanisms Received: January 06, 2017 linking nociceptive and cannabinoid signaling with TRP channels. Revised: April 04, 2017 Accepted: April 14, 2017 Results: We begin with an overview of physiology of the endocannabinoid system and its major DOI: components, namely CB1 and CB2 G protein-coupled receptors, their two most studied endogenous 10.2174/1570159X15666170424120802 ligands, anandamide and 2-AG, and several enzymes involved in endocannabinoid biosynthesis and degradation.
    [Show full text]
  • Fungal Infections (Mycoses): Dermatophytoses (Tinea, Ringworm)
    Editorial | Journal of Gandaki Medical College-Nepal Fungal Infections (Mycoses): Dermatophytoses (Tinea, Ringworm) Reddy KR Professor & Head Microbiology Department Gandaki Medical College & Teaching Hospital, Pokhara, Nepal Medical Mycology, a study of fungal epidemiology, ecology, pathogenesis, diagnosis, prevention and treatment in human beings, is a newly recognized discipline of biomedical sciences, advancing rapidly. Earlier, the fungi were believed to be mere contaminants, commensals or nonpathogenic agents but now these are commonly recognized as medically relevant organisms causing potentially fatal diseases. The discipline of medical mycology attained recognition as an independent medical speciality in the world sciences in 1910 when French dermatologist Journal of Raymond Jacques Adrien Sabouraud (1864 - 1936) published his seminal treatise Les Teignes. This monumental work was a comprehensive account of most of then GANDAKI known dermatophytes, which is still being referred by the mycologists. Thus he MEDICAL referred as the “Father of Medical Mycology”. COLLEGE- has laid down the foundation of the field of Medical Mycology. He has been aptly There are significant developments in treatment modalities of fungal infections NEPAL antifungal agent available. Nystatin was discovered in 1951 and subsequently and we have achieved new prospects. However, till 1950s there was no specific (J-GMC-N) amphotericin B was introduced in 1957 and was sanctioned for treatment of human beings. In the 1970s, the field was dominated by the azole derivatives. J-GMC-N | Volume 10 | Issue 01 developed to treat fungal infections. By the end of the 20th century, the fungi have Now this is the most active field of interest, where potential drugs are being January-June 2017 been reported to be developing drug resistance, especially among yeasts.
    [Show full text]
  • Marrakesh Agreement Establishing the World Trade Organization
    No. 31874 Multilateral Marrakesh Agreement establishing the World Trade Organ ization (with final act, annexes and protocol). Concluded at Marrakesh on 15 April 1994 Authentic texts: English, French and Spanish. Registered by the Director-General of the World Trade Organization, acting on behalf of the Parties, on 1 June 1995. Multilat ral Accord de Marrakech instituant l©Organisation mondiale du commerce (avec acte final, annexes et protocole). Conclu Marrakech le 15 avril 1994 Textes authentiques : anglais, français et espagnol. Enregistré par le Directeur général de l'Organisation mondiale du com merce, agissant au nom des Parties, le 1er juin 1995. Vol. 1867, 1-31874 4_________United Nations — Treaty Series • Nations Unies — Recueil des Traités 1995 Table of contents Table des matières Indice [Volume 1867] FINAL ACT EMBODYING THE RESULTS OF THE URUGUAY ROUND OF MULTILATERAL TRADE NEGOTIATIONS ACTE FINAL REPRENANT LES RESULTATS DES NEGOCIATIONS COMMERCIALES MULTILATERALES DU CYCLE D©URUGUAY ACTA FINAL EN QUE SE INCORPOR N LOS RESULTADOS DE LA RONDA URUGUAY DE NEGOCIACIONES COMERCIALES MULTILATERALES SIGNATURES - SIGNATURES - FIRMAS MINISTERIAL DECISIONS, DECLARATIONS AND UNDERSTANDING DECISIONS, DECLARATIONS ET MEMORANDUM D©ACCORD MINISTERIELS DECISIONES, DECLARACIONES Y ENTEND MIENTO MINISTERIALES MARRAKESH AGREEMENT ESTABLISHING THE WORLD TRADE ORGANIZATION ACCORD DE MARRAKECH INSTITUANT L©ORGANISATION MONDIALE DU COMMERCE ACUERDO DE MARRAKECH POR EL QUE SE ESTABLECE LA ORGANIZACI N MUND1AL DEL COMERCIO ANNEX 1 ANNEXE 1 ANEXO 1 ANNEX
    [Show full text]
  • Vr Meds Ex01 3B 0825S Coding Manual Supplement Page 1
    vr_meds_ex01_3b_0825s Coding Manual Supplement MEDNAME OTHER_CODE ATC_CODE SYSTEM THER_GP PHRM_GP CHEM_GP SODIUM FLUORIDE A12CD01 A01AA01 A A01 A01A A01AA SODIUM MONOFLUOROPHOSPHATE A12CD02 A01AA02 A A01 A01A A01AA HYDROGEN PEROXIDE D08AX01 A01AB02 A A01 A01A A01AB HYDROGEN PEROXIDE S02AA06 A01AB02 A A01 A01A A01AB CHLORHEXIDINE B05CA02 A01AB03 A A01 A01A A01AB CHLORHEXIDINE D08AC02 A01AB03 A A01 A01A A01AB CHLORHEXIDINE D09AA12 A01AB03 A A01 A01A A01AB CHLORHEXIDINE R02AA05 A01AB03 A A01 A01A A01AB CHLORHEXIDINE S01AX09 A01AB03 A A01 A01A A01AB CHLORHEXIDINE S02AA09 A01AB03 A A01 A01A A01AB CHLORHEXIDINE S03AA04 A01AB03 A A01 A01A A01AB AMPHOTERICIN B A07AA07 A01AB04 A A01 A01A A01AB AMPHOTERICIN B G01AA03 A01AB04 A A01 A01A A01AB AMPHOTERICIN B J02AA01 A01AB04 A A01 A01A A01AB POLYNOXYLIN D01AE05 A01AB05 A A01 A01A A01AB OXYQUINOLINE D08AH03 A01AB07 A A01 A01A A01AB OXYQUINOLINE G01AC30 A01AB07 A A01 A01A A01AB OXYQUINOLINE R02AA14 A01AB07 A A01 A01A A01AB NEOMYCIN A07AA01 A01AB08 A A01 A01A A01AB NEOMYCIN B05CA09 A01AB08 A A01 A01A A01AB NEOMYCIN D06AX04 A01AB08 A A01 A01A A01AB NEOMYCIN J01GB05 A01AB08 A A01 A01A A01AB NEOMYCIN R02AB01 A01AB08 A A01 A01A A01AB NEOMYCIN S01AA03 A01AB08 A A01 A01A A01AB NEOMYCIN S02AA07 A01AB08 A A01 A01A A01AB NEOMYCIN S03AA01 A01AB08 A A01 A01A A01AB MICONAZOLE A07AC01 A01AB09 A A01 A01A A01AB MICONAZOLE D01AC02 A01AB09 A A01 A01A A01AB MICONAZOLE G01AF04 A01AB09 A A01 A01A A01AB MICONAZOLE J02AB01 A01AB09 A A01 A01A A01AB MICONAZOLE S02AA13 A01AB09 A A01 A01A A01AB NATAMYCIN A07AA03 A01AB10 A A01
    [Show full text]
  • Cannabis Sativa: a Systematic Review of Plant Analysis
    Drug Analytical Research Drug Anal Res, 2017; 01, 1-23 Cannabis sativa: A systematic review of plant analysis Bruna Tassi Borillea*; Marina Gonzáleza; Luiza Steffensa; Rafael Scorsatto Ortizb; Renata Pereira Limbergera a Laboratório de Análises e Pesquisa em Toxicologia, Universidade Federal do Rio Grande do Sul, Departamento de Farmácia, Porto Alegre, 90610-000, RS, Brazil. b Divisão Técnico-Científica do Rio Grande do Sul, Polícia Federal Brasileira, Porto Alegre, 90160-092, RS, Brazil. *Corresponding author e-mail: [email protected] Background: Cannabis has been the most widely used illicit drug worldwide throughout many years. Reports from different countries indicate that the potency of cannabis preparation has been increasing, as well as the ratio of tetrahydrocannabinol/cannabidiol has been changing. The high consumption couple with the variable chemical profile of the drug is increasing gradually the interest in researching the cannabis plant. Methods: This article reviews available literature on the analytical methods currently used for the detection and quantification of cannabinoids in cannabis plant. The papers were screened by two independently researchers and following a pre-specified protocol. Results and Discussion: The systematic review of the literature allowed to include 42 citations on cannabis plant analysis and botanical aspects of cannabis. Conclusions: The analytical methods for cannabis material published in the included articles of this systematic review showed lack of relevant information of the development of methods on GC and LC analysis and the limits of detection and quantification of mass detectors. These information, on the methods of analysis, are essential and extremely important, since in the current scenario the analytical approach should consider the action of modulation CBD with THC, which alters the disruptive effects of the drug and also presents important pharmacological activity.
    [Show full text]
  • (Oral and Vaginal) Therapy for Recurrent Vulvovaginal Candidiasis: a Systematic Review Protocol
    Open access Protocol BMJ Open: first published as 10.1136/bmjopen-2018-027489 on 22 May 2019. Downloaded from Antifungal (oral and vaginal) therapy for recurrent vulvovaginal candidiasis: a systematic review protocol Juliana Lírio,1 Paulo Cesar Giraldo,2 Rose Luce Amaral,2 Ayane Cristine Alves Sarmento,3 Ana Paula Ferreira Costa,3 Ana Katherine Gonçalves3 To cite: Lírio J, Giraldo PC, ABSTRACT Strengths and limitations of this study Amaral RL, et al. Antifungal Introduction Vulvovaginal candidiasis (VVC) is frequent (oral and vaginal) therapy in women worldwide and usually responds rapidly to for recurrent vulvovaginal ► Two independent reviewers will select studies, ex- topical or oral antifungal therapy. However, some women candidiasis: a systematic tract data without different variables and assess develop recurrent vulvovaginal candidiasis (RVVC), which review protocol. BMJ Open the risk of bias, to indicate through evidence-based 2019;9:e027489. doi:10.1136/ is arbitrarily defined as four or more episodes every medicine if there is a more effective antifungal ther- bmjopen-2018-027489 year. RVVC is a debilitating, long-term condition that can apeutic regimen for the treatment of recurrent vul- severely affect the quality of life of women. Most VVC is Prepublication history for vovaginal candidiasis. ► diagnosed and treated empirically and women frequently this paper is available online. ► There may be a limitation of outcome from treat- To view these files, please visit self-treat with over-the-counter medications that could ment variation, routes of administration, different the journal online (http:// dx. doi. contribute to an increase in the antifungal resistance. The doses and quality of the randomised trials used in org/ 10.
    [Show full text]